Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SANA
SANA BIOTECHNOLOGY, INC.
NASDAQ
$3.93
▼ DOWN 3.91% (-0.16)

KEY STATISTICS

Market Cap$1.09 B
52w High$6.55
52w Low$2.61
Dividend Yield—
Frequency—
P/E-6.44
Volume2.14M
Shares Out.278.29M

COMPANY

LEADERSHIP

Steven D. Harr
CHIEF EXECUTIVE
Steven D. Harr

COMPENSATION 2026

Salary$696,140
Stock Awards$425,001
Incentive Plan Pay$450,369
All Other Comp.$4,000
Total$2,903,010

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 4, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
142

PRICE TARGET

Target High$12.00
Target Low$7.00
Target Median$7.00
Target Consensus$8.67

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$3.93 ▼ DOWN 3.91% (−$0.16)
$3.90$3.98$4.059:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.93

About Sana Biotechnology, Inc.

https://www.sana.com ↗

Sana Biotechnology develops engineered cell therapies for various diseases, including cancer, genetic disorders, and neurological conditions, with product candidates targeting cancers like lymphoma and multiple myeloma, and treatments for sickle c...

INDUSTRY

Biotechnology

A PRODUCT SANA BIOTECHNOLOGY, INC. IS KNOWN FOR

SC451
SC451

SC451 is an investigational cell therapy using engineered stem cell-derived pancreatic islet cells to treat Type 1 diabetes by enabling insulin production without immunosuppression, with an IND planned for 2026.

COMPETITORS

COMPETITOR
ALLO COMPARE
CRBU COMPARE
EDIT COMPARE
NTLA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
113
LISTED HERE
18
RANKED BY POSITION SIZE
XBI
0.26% · 7.5M
VTI
0.00% · 6.3M
XSU.TO
0.02% · 4.7M
SCHA
0.01% · 799.5K
PRFZ
0.06% · 390.9K
LABU
0.18% · 274.3K
XRSU.L
0.02% · 168.0K
BBC
0.91% · 117.0K
DFAS
0.00% · 110.7K
ONEQ
0.00% · 93.2K
RSSL
0.02% · 87.2K
WBIO.L
0.64% · 52.2K
TILT
0.00% · 22.4K
RFLR
0.06% · 13.9K
BIB
0.04% · 9.9K
VETS
0.06% · 5.4K
USFMDN.MX
0.00% · 839
RESM
0.02% · 340

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.81%
HOLDERS
280
TOP 12 OF 280 · RANKED BY POSITION SIZE
Fmr LLC
37.4M sh · $132.88M
Flagship Pioneering Inc.
25.0M sh · $87.26M
Ra Capital Management, L.P.
18.8M sh · $65.44M
Blackrock, Inc.
16.7M sh · $58.2M
Baillie Gifford & Co
11.4M sh · $40.6M
State Street Corp
11.2M sh · $39.1M
Blackrock Inc.
11.0M sh · $60.31M
Vanguard Group Inc
10.5M sh · $42.55M
Canada Pension Plan Investment Board
10.2M sh · $41.69M
Citadel Advisors LLC
6.6M sh · $23.26M
Bank Of America Corp /De/
5.7M sh · $20.06M
Geode Capital Management, LLC
4.7M sh · $16.33M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: EVP, CHIEF SCIENTIFIC OFFICER
PATEL DHAVALKUMAR DHIRAJLAL
Sale · 125.0K shares
2026-08-26
★
OFFICER: EVP, CHIEF SCIENTIFIC OFFICER
PATEL DHAVALKUMAR DHIRAJLAL
Purchase · 125.0K shares
2026-08-26
★
OFFICER: EVP, CHIEF SCIENTIFIC OFFICER
PATEL DHAVALKUMAR DHIRAJLAL
Sale · 41.2K shares
2026-08-27
★
DIRECTOR
Bishop Hans Edgar
Purchase · 6.3K shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
MARKET OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
B of A Securities BUY Wedbush OUTPERFORM HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
RLAY$18.77COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
NKTR$72.52COMPARE
XNCR$26.06COMPARE
INBX$123.41COMPARE
SNDX$19.54COMPARE